April 10, 2026

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.

Dry eye disease, also referred to as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome, is a multifactorial ocular surface disease characterized by ocular discomfort, irritation, and visual disturbance. It ranks among the most frequently encountered ocular morbidities, with more than 25% of patients attending ophthalmic clinics reporting these symptoms (Dana et al. 2019).

The global prevalence of dry eye disease is estimated to range from 7% to 34%, depending on diagnostic criteria and the population surveyed (Deo and Nagrale 2024). The steep rise in annual dry eye disease incidence and prevalence over the past decade has recently been estimated (Zhang et al. 2024).

In 2002, Dursun and colleagues published a mouse model of dry eye disease by combining application of transdermal scopolamine patches together with a desiccating environmental stress (Dursun et al. 2002). At Experimentica, we use corneal fluorescein staining (CFS) to confirm successful model induction.

Figure 1. Corneal fluorescein staining of damaged epithelial cell layer.

CFS is scored using the modified Oxford score method by assigning scores from 0 (healthy corneal epithelial cell layer with no observable fluorescein staining) to 4 (severe corneal epithelial cell damage with widespread confluent staining of the cornea.

Figure 2. Corneal fluorescein score at Day 21 of the study follow-up in naïve, untreated and PBS-treated eyes.

In addition, the evaluation of dry eye disease-like pathology can be performed with tear volume measurements and histological assessment of immune cell infiltration in lacrimal glands, quantification of goblet cells in the conjunctiva or corneal thickness and the number of corneal epithelial layers.

Figure 3. H&E staining of lacrimal gland, PAS staining of Goblet cells, and H&E staining of cornea.

Contact us for more information or schedule the meeting with our experts!

Contact usLearn more about our Dry Eye Disease model

References

Our latest News

discover more
Digital recording of health status

Digital recording of health status

Successful pilot project at Heidelberg University Hospital Regularly surveying patients about their health-related quality of life is a key aspect of patient-centred medicine. At Heidelberg University Hospital, a new digital system is being used for this purpose in a pilot project: patients complete online questionnaires on their own mobile devices, after which the data is […]

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities. Dry eye disease, also referred […]

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Foster City, Calif., and Munich, Germany – April 7, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need. The acquisition significantly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp